Pay in 4 interest-free payments of $5.96 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
The clinical data on AOD-9604 demonstrates remarkable hormonal stability, with no effects on cortisol, thyroid hormones, sex hormones, or the growth hormone/IGF-1 axis
In practice, a researcher selecting between them is usually choosing which mechanistic question to probe: vascular and cytoprotective signaling points toward BPC-157, while questions dominated by cell migration and cytoskeletal dynamics point toward TB-500
Baseline bloodwork CBC, CRP, ferritin, IL-6, cortisol AM, metabolic panel, thyroid function Cardiovascular assessment heart rate variability, orthostatic vitals if POTS is suspected Gut health markers stool testing, zonulin, calprotectin if GI symptoms are prominent Mitochondrial function proxies lactate, organic acids panel if PEM is a primary complaint From there, a typical protocol might be structured as: Phase 1 (Weeks 16): Immune and gut foundation Thymosin Alpha-1: 1.6 mg subcutaneous, twice weekly BPC-157: 250500 mcg daily, route determined by predominant symptom (oral for gut, injectable for systemic) Phase 2 (Weeks 412): Tissue repair and cardiovascular recovery TB-500: 2.02.5 mg subcutaneous, twice weekly Continue BPC-157 as indicated Phase 3 (Weeks 816): Maintenance and metabolic support Taper or pulse doses based on clinical response Add mitochondrial support if fatigue persists (see: Mitochondrial Peptides and Insulin Resistance) These are illustrative dosing ranges based on clinical research and published protocols
Getting regular blood work is another way to remove the blood and reduce iron load regularly
Adjust your unit calculations accordingly
Low energy
